[HTML][HTML] The molecular mechanisms of immunomodulation and tolerance induction to factor VIII
B Waters, D Lillicrap - Journal of thrombosis and haemostasis, 2009 - Elsevier
Successful factor (F) VIII replacement therapy in hemophilia A patients is confounded by the
generation of inhibitory anti‐FVIII antibodies (Ab) in 25–30% of treated patients. These
antibodies, termed 'inhibitors', significantly increase morbidity within the hemophilia
population and lower the quality of life for these patients. For the past 30 years, immune
tolerance induction (ITI) has been the standard therapy to elicit immunological tolerance to
FVIII in the clinic. ITI works well in approximately 75% of patients, but it is expensive, can …
generation of inhibitory anti‐FVIII antibodies (Ab) in 25–30% of treated patients. These
antibodies, termed 'inhibitors', significantly increase morbidity within the hemophilia
population and lower the quality of life for these patients. For the past 30 years, immune
tolerance induction (ITI) has been the standard therapy to elicit immunological tolerance to
FVIII in the clinic. ITI works well in approximately 75% of patients, but it is expensive, can …
